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Mission of the Annual Postdoctoral Science Symposium 
 
To provide a platform for talented postdoctoral fellows throughout the Texas 
Medical Center to present their work to a wider audience, the MD Anderson 
Postdoctoral Association convened the inaugural Annual Postdoctoral Science 
Symposium (APSS) on August 4, 2011. 
 
The APSS provides a professional venue for postdoctoral scientists to develop, 
clarify, and refine their research as a result of formal reviews and critiques of 
faculty and other postdoctoral scientists. Additionally, attendees discuss current 
research on a broad range of subjects while promoting academic interactions 
and enrichment and developing new collaborations. 
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Oral Presentations 
 
 
 
 
Oral presentations were submitted for the following three categories: Applied 
Science, Basic Research, and Clinical/Translational Research. Each category 
included four (4) presenters. 
 
Please note that only abstracts of presenters who agreed to have their abstracts 
published are included. 
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APPLIED SCIENCE 
Conjugation of HOPO to protein and radiolabeling with Zr-89: 
Comparative stability and biodistribution in normal mice 
Bhasker Radaram, Sandun Perera, David Piwnica-Worms, Mian M. Alauddin 
Department of Cancer Systems Imaging, The University of Texas MD Anderson 
Cancer Center, Houston, TX. 
 
Objectives: Zirconium-89 (89Zr) is attractive for use in antibody-based positron 
emission tomography due to its radiodecay half-life compatible with the biological 
half-life of antibodies. Physicians have commonly used deferoxamine (DFO) as a 
chelating agent for this purpose.1 However, DFO-chelated 89Zr can suffer from in 
vivo stability challenges.2 A new chelating agent, 3,4,3-(LI-1,2-HOPO) (HOPO), 
has demonstrated efficient binding of 89Zr with high stability.3 We have 
synthesized three analogs of HOPO exhibiting high in vitro and in vivo stability 
with 89Zr. We present conjugation of HOPO to protein, radiolabeling with 89Zr, 
stability of the labeled protein conjugates, and their biodistribution results. 
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Methods: Chemistry: Figure 1 shows the scheme for synthesis of one ligand. 
Briefly, N-protected amino-alkyl iodide was reacted with spermine. The 
monosubstituted spermine derivative was reacted with HOPO acid chloride to 
obtain a substituted spermine-HOPO derivative. The amino protecting group from 
the spermine-HOPO derivative was hydrolyzed by acid, and the amino-alkyl-
spermine-HOPO reacted with phenylene-di-isothiocyanate to obtain p-SCN-
phenyl-alkyl-spermine-HOPO. 
Conjugation and radiolabeling: p-SCN-phenyl-C5-spermine-HOPO was 
conjugated with human or bovine serum albumin and purified, and the 
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conjugated proteins were radiolabeled with 89Zr-oxalate. After purification on a 
PD-10 column, the products were tested for in vitro stability and biodistribution. 
Animal study: Two groups of healthy athymic nude mice (n=4/group) were 
intravenously injected with 89Zr-HOPO-BSA or 89Zr-DFO-BSA (12-20 Ci) in 
phosphate-buffered saline. Mice were scanned every 24 hours up to 48 hours for 
positron emission tomography. After imaging, all mice were sacrificed; their 
blood, muscle, bone, heart, lungs, liver, spleen, pancreas, intestines, stomach, 
and kidneys were isolated and weighed; and their radioactivity was measured 
using a gamma counter. Radioactivity accumulation was expressed as percent 
injected dose per gram (%ID/G) and averaged with standard deviation. 
 
Results: We synthesized HOPO analogs in four steps with an overall yield of 
10%. The stability of 89Zr-HOPO-albumin in both human and mouse serum and 
at different pH (5, 6, 7, and 8) remained intact and exhibited better stability than 
that of 89Zr-DFO-albumin. Preliminary biodistribution of 89Zr-HOPO-protein in 
normal mice indicated good stability and greater uptake in the liver, spleen, and 
kidneys. 
 
Conclusion: We achieved radiolabeling of protein with 89Zr using p-SCN-phenyl-
alkyl-spermine-HOPO with different carbon chain lengths. In vitro and in vivo 
stability suggest that 89Zr-labeled protein using HOPO as a chelating agent is 
more stable than DFO-conjugated products. Further in vivo studies with 89Zr-
DFO- and 89Zr-HOPO-monoclonal antibodies are in progress for comparison. 
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References 
[1] J. Holand, V. Divilov, N. Bander, et al. J. Nucl. Med. 2010, 51, 1293-1300. 
[2] M. Deri, S. Ponnala, B. Zeglis, et al. J. Med. Chem. 2014, 57, 4849-4860. 
[3] M. Deri, S. Ponnala, P. Kozlowski, et al. Bioconjugate Chem. 2015, 26, 2579-
2591. 
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Identifying smokers at higher risk for relapse: Validation of a 
neuroimaging-based classification algorithm 
David W. Frank1, Menton E. Deweese1, Maher Karam-Hage1, Jason D. 
Robinson1, Damon J. Vidrine2, Paul M. Cinciripini1, Francesco Versace1 
1Department of Behavioral Science, The University of Texas MD Anderson 
Cancer Center, Houston, TX; 2Oklahoma Tobacco Research Center, University 
of Oklahoma, Oklahoma City, OK. 
 
Progress in basic neuroscience has improved our understanding of addiction 
neurobiology, but translating this knowledge into effective relapse-preventing 
treatments has proven to be difficult.1 Recently, we reported that smokers with 
larger event-related potentials (a direct measure of brain activity) to cigarette-
related cues compared with pleasant stimuli (C>P) are more likely to have 
relapses than are smokers with the opposite brain reactivity profile (P>C). We 
hypothesized that this neurobiological marker could be used to identify smokers 
with high vulnerability to relapse. In this study, we aimed to 1) build a 
classification algorithm to identify, on a case-by-case basis, smokers 
characterized by the P>C or C>P event-related potential profiles and 2) validate 
the clinical relevance of this classification algorithm using an independent data 
set in which we assessed smoking abstinence during quit attempts by smokers 
classified as P>C or C>P. To build the classification algorithm, we applied 
discriminant function analysis to a data set in which we originally observed a 
significant association between smoking abstinence and neural reactivity to 
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emotional stimuli. We confirmed the predictive validity of the classification 
algorithm in an independent data set that included new data from 177 smokers 
interested in quitting. For each participant, we collected event-related potentials 
to emotional images before the quit attempts and assessed smoking abstinence 
12 months after the quit attempts. Using brain responses, the algorithm classified 
111 smokers as P>C and 66 as C>P. A low overall abstinence rate 
notwithstanding (8.5% of the sample achieved CO-verified 12-month abstinence), 
individuals classified as P>C were 2.5 times more likely to be abstinent than were 
smokers classified as C>P (12.0% vs. 4.8%). Although this difference was not 
statistically significant (p=0.08), these results suggest that neuroimaging 
techniques can help advance our knowledge of the neurobiological 
underpinnings of nicotine addiction and improve clinical applications. 
 
Reference 
[1] B.J. Everitt. Eur. J. Neurosci. 2014, 40, 2163-2182. 
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BASIC RESEARCH 
Lipocalin 2 promotes inflammatory breast cancer tumorigenesis 
and skin invasion 
Emilly Schlee Villodre1,10, Richard Larson2,10, Xiaoding Hu1,10, Shane R. 
Stecklein2,10, Kristen Gomez6, Pascal Finetti8, Savitri Krishnamurthy5,10, Cristina 
Ivan3, Xiaoping Su4, Naoto T. Ueno1,10, Steve Van Laere7, Francois Bertucci8, 
Debu Tripathy1,10, Pablo Vivas-Mejía9, Wendy A. Woodward2,10, Bisrat G. 
Debeb1,10 
1Department of Breast Medical Oncology, The University of Texas MD Anderson 
Cancer Center, Houston TX; 2Department of Radiation Oncology, The University 
of Texas MD Anderson Cancer Center, Houston, TX; 3Department of 
Experimental Therapeutics, The University of Texas MD Anderson Cancer 
Center, Houston, TX; 4Department of Bioinformatics and Computational Biology, 
The University of Texas MD Anderson Cancer Center, Houston, TX; 5Department 
of Pathology, The University of Texas MD Anderson Cancer Center, Houston, 
TX; 6Department of Biological Sciences, The University of Texas at Brownsville, 
Brownsville, TX; 7Department of Oncology, University of Antwerp, Antwerpen, 
Belgium; 8Department of Medical and Predictive Oncology Aix-Marseille 
Université, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille, France; 
9Department of Biochemistry and Cancer Center, University of Puerto Rico, San 
Juan, PR; 10Morgan Welch Inflammatory Breast Cancer Clinic and Research 
Program, The University of Texas MD Anderson Cancer Center, Houston, TX. 
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Background: Inflammatory breast cancer (IBC) is the most lethal form of primary 
breast cancer and accounts for a significant percentage of breast cancer deaths 
in the United States (10%) owing to its aggressive proliferation and metastasis 
and a lack of effective therapeutic options. Unraveling the underlying 
mechanisms of growth and metastasis of this aggressive disease could lead to 
effective therapeutic strategies that improve outcomes in IBC patients. We 
recently generated in vitro and in vivo IBC models for brain metastasis studies1 
and observed dramatic upregulation of lipocalin-2 (LCN2), a small, secreted iron-
trafficking protein that plays a significant role in immune and inflammatory 
responses and the promotion of malignant progression. We hypothesized that 
LCN2 facilitates progression and metastasis of IBC. 
 
Methods: Stable knockdown (KD) of LCN2 in IBC cell lines was achieved with 
lentiviral vectors. Proteomic and gene expression profiling were performed using 
a reverse-phase protein array and Affymetrix Clariom D microarray. For in vivo 
studies, control and LCN2-KD IBC cells were transplanted into the cleared 
mammary fat pads of severe combined immunodeficiency/beige mice. Tumor-
skin involvement was assessed visually during primary tumor growth and tumor 
excision. LCN2 gene expression levels in clinical samples were analyzed by the 
IBC Consortium as well as using public data sets. LCN2 serum levels in IBC 
patients were measured using an enzyme-linked immunosorbent assay and were 
correlated with clinicopathological variables and outcome data. 
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Results: LCN2 gene expression was higher in IBC than in non-IBC patients 
(p=0.00036) independent of the molecular subtype of breast cancer and higher in 
more aggressive (triple-negative and HER2+) than in hormone receptor-positive 
subtypes (p<0.00001). LCN2 expression in patient tissue was correlated with 
reduced overall survival (p<0.00001) and metastasis-free survival (p=0.04) in 
non-IBC patients. However, LCN2 expression was not associated with overall 
survival in IBC patient serum samples. LCN2 expression was also significantly 
higher in IBC cell lines, their culture media, and brain metastasis sublines than in 
non-IBC cell lines (p=0.004). In IBC cell lines, LCN2 KD reduced proliferation, 
colony formation, migration, and cancer stem cell properties. In vivo silencing of 
LCN2 in SUM149 cells inhibited primary tumor growth (p=0.001) and resulted in 
a well-differentiated tumor histology. Additionally, LCN2 KD in SUM149 cells 
significantly reduced skin invasion/recurrence (control LCN2 vs. LCN2-KD cells, 
88% vs. 25%; p=0.01), suggesting that LCN2 is a mediator of tumorigenesis. 
Analysis of proteomic data demonstrated changes in major signaling pathways, 
including PI3K-Akt signaling and EGF/EGF receptor signaling pathways. 
Mechanistically, LCN2 depletion in SUM149 cells abrogated EGF-induced EGF 
receptor phosphorylation and extracellular signal-regulated kinase activation. 
 
Conclusions: Our findings suggest that LCN2 drives IBC progression and skin 
invasion/recurrence potentially via the EGF receptor signaling pathway. Future 
studies will determine the role of LCN2 in metastasis and pinpoint the detailed 
mechanisms of LCN2-mediated IBC tumorigenesis and recurrence. 
11 
 
Reference 
[1] B.G. Debeb, L. Lacerda, S. Anfossi, et al. J. Natl Cancer Inst. 2016, 108. 
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CLINICAL/TRANSLATIONAL RESEARCH 
Metabolomic profiling improves prediction of minimal residual 
disease and reveals potential metabolic vulnerabilities in 
pediatric acute lymphoblastic leukemia 
Jeremy Schraw1, Jacob Junco2, Austin Brown2, Michael Scheurer2, Karen 
Rabin2, Philip Lupo2 
1Department of Medicine, Section of Epidemiology and Population Sciences, 
Baylor College of Medicine, Houston, TX; 2Department of Pediatrics, Section of 
Hematology-Oncology, Baylor College of Medicine, Houston, TX. 
 
Background/Objectives: End-induction minimal residual disease (MRD) is the 
most important predictor of relapse of pediatric acute lymphoblastic leukemia. 
However, many relapses occur in MRD-negative patients. We hypothesized that 
global metabolomic profiling of diagnostic bone marrow plasma can improve 
prediction of MRD and provide insight into the biology of relapse. 
 
Design/Methods: We retrospectively identified 99 patients who received 
diagnosis and treatment at Texas Children’s Hospital from 2007 to 2015, of 
whom 39 were MRD-positive and 60 were MRD-negative at end-induction, using 
a cutoff of 0.01%. Diagnostic bone marrow plasma was subjected to 
metabolomic profiling via ultra-performance liquid chromatography-tandem mass 
spectrometry. The nonparametric Kruskal-Wallis test was used to compute 
univariate p values comparing MRD-positive and -negative plasma, and 
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metabolite set enrichment analysis was used to identify pathways enriched in 
differentially abundant metabolites with the Kyoto Encyclopedia of Genes and 
Genomes as the reference. Metabolites with univariate p values up to 0.001 were 
evaluated in logistic regression models for MRD, and the best predictors were 
obtained via backward elimination. The performance of models for MRD was 
assessed using clinical features alone and clinical features plus metabolites via 
DeLong’s test for correlated receiver operating characteristic curves. Also, the in 
vitro cytotoxicity of drugs targeting top-scoring pathways in acute lymphoblastic 
leukemia cell lines was measured using flow cytometric staining for annexin 
V/propidium iodide. 
 
Results: Metabolite set enrichment analysis revealed central carbon metabolism 
to be the pathway most enriched in differentially abundant metabolites (p=4.00E-
06). The levels of the constituent metabolites pyruvate, succinate, fumarate, and 
malate were all significantly increased in MRD-positive patients (p≤0.001). A 
predictive model for MRD incorporating these metabolites outperformed clinical 
features alone (area under the curve, 0.86 vs. 0.73; p=0.001). FK866, a 
nicotinamide phosphoribosyltransferase inhibitor that depletes these metabolites, 
exhibited significant cytotoxicity in five of six acute lymphoblastic leukemia cell 
lines (half-maximal inhibitory concentrations, 1-10 nM). 
 
Conclusion: Metabolomic profiling improved prediction of subsequent MRD and 
identified potentially druggable metabolic alterations. If validated, these 
14 
 
biomarkers may improve risk prediction and our understanding of disease 
biology. 
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Poster Presentations 
 
 
 
 
A total of 54 posters were accepted for presentation during the 2018 symposium. The 
names of the presenting postdocs are shown in boldface. 
 
Please note that only abstracts of presenters who agreed to have their abstracts 
published are included. 
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A hybrid agent-based particle and partial differential 
equations method to analyze vascular adaptation 
Marc Garbey1,2,3, Stefano Casarin1,3, Scott A. Berceli4,5 
1Center for Computational Surgery, Houston Methodist Research Institute, 
Houston, TX; 2Department of Surgery, Houston Methodist Hospital, Houston, TX; 
3LaSIE, UMR CNRS 7356, University of La Rochelle, La Rochelle, France; 
4Department of Surgery, University of Florida, Gainesville, FL; 5Malcom Randall 
VAMC, Gainesville, FL. 
 
Introduction: Peripheral arterial occlusive disease is a chronic pathology 
affecting at least 8-12 million people in the United States that is typically treated 
with a vein graft bypass or deployment of a stent to restore the physiological 
circulation. Failure of peripheral endovascular interventions occurs at the 
intersection of vascular biology, biomechanics, and clinical decision-making. We 
hypothesize that the majority of endovascular treatment approaches share the 
same driving mechanisms and that a deep understanding of the adaptation 
process is pivotal to improving outcomes of the procedure. The postsurgical 
adaptation of vein graft bypasses offers the perfect example of how the balance 
between intimal hyperplasia and wall remodeling determines the failure or 
success of the intervention. 
 
Methods: Presented is a versatile computational model able to capture the 
feedback loop that describes the interaction between events at the cellular/tissue 
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level and mechano-environmental conditions. This work is a generalization and 
improvement of a previous work by our group of investigators in which the graft is 
approximated as a thick cylinder and an agent-based model is used as a cellular 
automaton principle on a fixed hexagonal grid to reproduce the leading events of 
the graft's restenosis. 
 
Results: The new hybrid model facilitates a more realistic simulation of both the 
biological laws that drive cellular behavior and the active role of the membranes 
that separate the various layers of a vein. The novel feature is use of an 
immersed boundary implementation of a highly viscous flow to represent cellular 
motility and matrix reorganization in response to graft adaptation. Our 
implementation is modular, which makes us able to choose the right compromise 
between closeness to the physiological reality and complexity of the model. 
Finally, quantitative cross-validation with previously developed and validated 
zero-D models and qualitative validation with histological data from a rabbit 
model of intimal hyperplasia has been conducted, with satisfactory results. 
 
Discussion: Our model offers a new modular implementation that combines the 
best features of an agent-based model, continuum mechanics, and particle-
tracking methods to cope with the multiscale nature of the adaptation 
phenomenon. This hybrid method enables us to quickly test various hypotheses, 
with particular attention to cellular motility, a process that we demonstrated 
should be driven by mechanical homeostasis to maintain the right balance 
18 
 
between cells and the extracellular matrix to reproduce a distribution similar to 
histological experimental data from vein grafts. 
 
Conclusion: A detailed description of the complex network that regulates 
restenosis phenomena offers great potential to control the disease, driving 
therapy toward a better outcome. 
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Nanofluidic drug-eluting seed for sustained intratumoral 
immunotherapy for cancer treatment 
Corrine Ying Xuan Chua1, Antonio Susnjar1, Jeremy Ho1, Jessica Rhudy1, Priya 
Jain1, Marco Folci1,2, Andrea Ballerini1,3, April Gilbert1, Shailbala Singh4, Giacomo 
Bruno1,5, Cassian Yee4, Brian E. Butler1, Alessandro Grattoni1 
1Department of Nanomedicine, Houston Methodist Research Institute, Houston, 
TX; 2Department of Allergy and Clinical Immunology, Istituto Auxologico Italiano, 
University of Milan, Milan, Italy; 3Department of Medical Biotechnology and 
Translational Medicine, University of Milan, Milan, Italy; 4Department of 
Melanoma Medical Oncology, The University of MD Anderson Cancer Center, 
Houston, TX; 5Politecnico di Torino, Turin, Italy. 
 
Although the clinical breakthrough of treatment with immune checkpoint inhibitors 
such as nivolumab and ipilimumab in certain cancers has fueled optimism about 
immunotherapy, its efficacy is limited to a small subset of patients. In addition to 
insufficient antitumor immune response, systemic administration causes adverse 
side effects, with up to 91% of treated patients experiencing clinically significant 
immune-related adverse events. Intratumoral immunotherapy delivery has 
demonstrated antitumor efficacy in preclinical and clinical studies with minimal 
systemic toxicity. However, despite encouraging results, the feasibility of 
intratumoral injection is restricted to accessible solid tumors, whereas 
inaccessible tumors require technically challenging image-guided injections. To 
fulfill the unmet need for sustained local drug delivery and avoid repeated 
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intratumoral injections, we developed the nanofluidic drug-eluting seed (NDES), 
a device the size of a grain of rice, for intratumoral drug delivery. The NDES is 
inserted intratumorally using a minimally invasive trocar-based method similar to 
brachytherapy seed insertion and offers the clinical benefit of drug elution. Drug 
release from the NDES is driven by a difference in concentration, allowing for 
sustained intratumoral immunotherapy delivery without the need for injections, 
actuation, or clinician intervention. In this study, we used the NDES to deliver 
immunotherapy intratumorally in the 4 T1 orthotopic murine mammary carcinoma 
model, which recapitulates triple-negative breast cancer. We demonstrated that 
NDES-mediated intratumoral release of the agonist monoclonal antibodies OX40 
and CD40 resulted in potentiation of local and systemic antitumor immune 
response and inhibition of tumor growth, unlike the control treatment. 
Furthermore, mice given NDES-CD40 had minimal systemic drug exposure and 
liver damage in contrast with systemically treated mice. Because CD40-based 
monotherapy was insufficient to eliminate tumor burden, we speculated that 
maximal therapeutic synergy could be achieved using combination treatment with 
radiation to induce immunogenic cell death. In line with this, in combination with 
localized irradiation, NDES-CD40 was more effective at reducing tumor burden 
than was monotherapy. Overall, we found that the NDES is an effective platform 
for sustained intratumoral immunotherapy delivery with potential for clinical 
translation given that the NDES is applicable to a broad spectrum of drugs and 
solid tumors. 
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An Exploratory factor analysis of patient-centered cancer care 
measures to support improved assessment of patients’ 
experiences 
Kerri-Anne Parkes1, Bryan Fellman2, Kelly Brassil1 
1Department of Nursing, The University of Texas MD Anderson Cancer Center, 
Houston, TX; 2Department of Biostatistics, The University of Texas MD Anderson 
Cancer Center, Houston, TX. 
 
Background: Cross-cutting quality measures developed with strong 
psychometric properties and patient input are critical to assessing and achieving 
high-quality patient-centered cancer care. 
 
Objective: In the present study, patient-centered cancer care dimensions were 
examined using exploratory factor analysis, and their relationships with 
demographic characteristics and cancer site were assessed. 
 
Methods: Exploratory factor analysis was performed using the modified Patients 
and the Cancer Care Experience Survey, a patient-reported measure of 
perceived importance of social, emotional, physical, and informational aspects of 
cancer care administered to adult patients at a National Cancer Institute-
designated comprehensive cancer center. Bivariate analyses were performed 
using the Wilcoxon rank-sum test. 
 
22 
 
Results: The exploratory factor analysis revealed a five-factor model: 1) quality 
of life, 2) provider social support, 3) psychosocial needs, 4) nonprovider social 
support, and 5) health information and decision-making support. We found 
statistically significant associations between these factors and patients’ 
demographic characteristics and cancer sites. Female participants (p=0.036) and 
those younger than 60 years (p=0.036) were more concerned about quality of 
life. Participants with prostate cancer were more concerned about social support 
from providers (p=0.035) and psychosocial needs (p=0.002). Lung cancer 
patients were less concerned about psychosocial needs (p=0.029).  
 
Conclusions: All of the dimensions of existing patient-centered care models 
were supported by the identified model. One exception, care coordination, was 
not significant, perhaps due to overlap with another factor or the small sample 
size. Increased understanding of patient-centered cancer care and its 
associations with patient characteristics can support practice changes to improve 
patients’ cancer care experiences. 
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Sheeba J. Sujit1, Refaat E. Gabr1, Ivan Coronado1, Melvin Robinson2, Sushmita 
Datta1, Ponnada A. Narayana1 
1Department of Diagnostic and Interventional Imaging, The University of Texas 
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Automated evaluation of image quality is essential to assuring accurate diagnosis 
and patient management. This is particularly important for multicenter studies, 
typically employed in clinical trials, in which data are acquired using different 
machines with different protocols. Visual quality assessment of magnetic 
resonance imaging (MRI) is subjective and impractical for large data sets. Data-
intensive deep learning methods such as convolutional neural networks (CNNs) 
are promising tools for processing large-scale imaging data sets for automated 
quality assessment. In this study, we focused on quality evaluation of the Autism 
Brain Imaging Data Exchange structural brain MRI data set acquired from 17 
sites on more than 1000 subjects using CNNs. The multilayer deep learning 
architecture consisted of an input layer, four convolution layers, two fully 
connected layers, and an output layer. We selected 378 image volumes to 
balance between the acceptable and unacceptable based on expert evaluation. 
Sixty percent of the data were used for training, 15% were used for validation, 
and 25% were used for testing. The results of the automated approach were 
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compared with evaluation by a radiologist. Performance of the CNN was 
assessed using a confusion matrix from which the sensitivity, specificity, and 
accuracy were calculated. The concordance in the image quality label between 
the expert and CNN was 86% (sensitivity, 81%; specificity, 92%). This study 
demonstrated that the proposed algorithm can be used to evaluate the quality of 
brain MRI with greater classification accuracy than previous state-of-the-art 
classical machine learning algorithms. We did all processing using the Maverick 
2 cluster at the Texas Advanced Computing Center in Austin, TX. We used 
NVIDIA Tesla GTX graphical processing unit cards and carried out 
implementation in the Python computing language using the Keras library and 
TensorFlow.  
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Inhibition of autophagy kinase ULK1 combined with 
chemotherapy results in modulation of reactive oxygen species 
and DNA damage response to induce synergistic cell death in 
acute myeloid leukemia 
Seemana Bhattacharya, Sujan Piya, Teresa McQueen, Marina Konopleva, 
Michael Andreeff, Gautam Borthakur 
Department of Leukemia, The University of Texas MD Anderson Cancer Center, 
Houston, TX. 
 
Introduction: Cytarabine (Ara-C)-based chemotherapy has been the backbone 
of acute myeloid leukemia (AML) treatment, but relapses are common in adults. 
Targeted therapies are approved for only a few specific mutations and yield 
limited responses. Several chemotherapeutic agents used in AML chemotherapy 
induce cytoprotective autophagy, conferring drug resistance.1 Autophagy 
protects quiescent hematopoietic stem cells from metabolic stress by maintaining 
low intracellular reactive oxygen species (ROS) levels.2 Impaired autophagy is 
associated with increased oxidative metabolism, and ROS production causes 
loss of quiescence due to oxidative stress.3 Leukemic stem cells are more 
dependent on oxidative metabolism and, hence, more sensitive to oxidative 
stress.4 
 
Our previous work demonstrated that autophagy inhibition (genetic knockdown of 
Atg7) enhances AML sensitivity to standard therapies (Ara-C and idarubicin).5 
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Because ULK1 is an apical kinase in the autophagy pathway, we hypothesized 
that targeting ULK1 can inhibit autophagy and alter intracellular ROS in AML 
cells. This would help overcome chemoresistance by modulating ROS. We also 
elucidated the mechanistic details. 
 
Methods: ULK1 expression was genetically altered in OCI-AML3 human AML 
cells by shRNA-knockdown or CRISPR/Cas9 knockout. In addition, AML cells 
and patient samples were treated with Ara-C and the ULK1 inhibitor SBI-
0206965.6 The combination index for drug synergy was calculated based on the 
Chou-Talalay method.7 Autophagy was detected using LC3 quantification 
(Western blotting and flow cytometry) and acridine orange and 
monodansylcadaverine assays. Other assays used were ROS, mass cytometry 
(cytometry by time of flight), reverse-phase protein array, glutathione, Western 
blotting, and real-time PCR. 
 
Results: Ara-C induced autophagy (twofold to fourfold in all assays). ULK1 
knockdown/knockout enhanced Ara-C–mediated cytotoxicity by 25% ± 3% and 
47% ± 5%, respectively (p<0.01). Similarly, concomitant treatment with the ULK1 
inhibitor SBI-0206965 enhanced Ara-C–induced death of OCI-AML3 (from 44% 
to 60%; p=0.23) and MOLM13 (from 33% to 85%; p=0.0003) cells over that by 
ara-C alone. The combination was also effective in eliminating bulk and CD34+ 
stem/progenitor populations among primary AML cells (combination index: bulk, 
0.68; CD34+, 0.69; p<0.05). 
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SBI-0206965 alone induced ROS in AML cells (62% ± 13%; p=0.013). This was 
associated with ATM activation and DNA damage (PARP and caspase 3 
cleavage, H2AX phosphorylation). The ROS quencher N-acetylcysteine could 
partially mitigate the DNA damage, confirming the role of ROS in that damage 
(shown via Western blotting). Ara-C increased ROS levels (62% ± 3%; p=0.004), 
and the combination with SBI-0206965 further enhanced ROS generation (115% 
± 9%; p=0.01). Again, N-acetylcysteine reduced ROS levels to 42% (p=0.011). 
Thus, the combination generated excess ROS, which accounts for increased 
DNA damage. 
 
Mechanistically, an increased ROS level upon ULK1 inhibition was associated 
with intracellular glutathione. Glutathione is regulated by the cysteine-glutathione 
antiporter system (xCT/CD44). ULK1 inhibition by SBI-0206965 downregulated 
transcripts of CD44 and its variant (v8-10) by 86% and 81%, respectively 
(p=0.001). The xCT and CD44 proteins were also downregulated. When we 
injected control and ULK1-knockout cells into NSG mice, we observed a marked 
delay in leukemia engraftment in the ULK1-knockout group. Further studies are 
ongoing. 
 
Conclusions: Autophagy prevents maximal apoptosis induced by chemotherapy 
in AML cells. Our study demonstrated single-agent activity of the ULK1 inhibitor 
SBI-0206965 and enhanced efficacy of chemotherapy combined with ULK1 
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inhibition. This combination potentiates chemotherapy-induced DNA damage by 
reversing drug-induced autophagy and modulating intracellular ROS through 
xCT/CD44. 
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TP73 isoforms (TAp73 and Np73) are overexpressed in acute 
myeloid leukemias and potential therapeutic targets to enhance 
anti-leukemia activities of Bcl-2 and MDM2 inhibitors 
Yuki Nishida, Jo Ishizawa, Vivian R. Ruvolo, Michael Andreeff 
Department of Leukemia, The University of Texas MD Anderson Cancer Center, 
Houston, TX. 
 
Background: TP73 is one of the TP53 family transcription factors and generates 
two isoforms, transactivation of p73 (TAp73) and N-terminally truncated p73 
(Np73). TAp73 shares a homologous N-terminal activation domain with p53 and 
has proapoptotic function similar to that of p53. Np73 lacks an activation 
domain and has activities distinct from those of TAp73. Np73 has a dominant-
negative effect on the DNA binding of TAp73 and, more importantly, p53, as the 
DNA-binding domain is homologous with that of TAp73 and highly similar to that 
of p53. Authors have reported TP73 to be expressed in acute myeloid leukemia 
(AML) cells but not acute promyelocytic leukemia cells. However, the association 
of TP73 isoforms with clinical and genetic characteristics of and regulation of the 
isoforms in AML cases have yet to be explored. 
 
Results: We determined copy numbers of Np73 and TAp73 mRNA levels in 78 
AML samples, including 31 de novo AML samples, using droplet digital PCR 
(ddPCR), and investigated their clinical and biological relevance. We detected 
Np73 and TAp73 expression in 93.6% and 98.7% of AML samples, 
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respectively, at various levels (mean [± standard error of the mean], 10.6 ± 5.0 
and 106.6 ± 33.7 copies/L for Np73 and TAp73, respectively). Np73 and 
TAp73 mRNA levels were highly correlated (R2 = 0.72; p<0.0001). Normal 
peripheral blood mononuclear cells and CD34+ hematopoietic cells had little or 
no Np73 or TAp73 expression (0.09 ± 0.09 and 0.42 ± 0.35 copies/L, 
respectively), demonstrating that expression of Np73 and TAp73 is 100-fold to 
1000-fold higher in AML cells than in normal hematopoietic cells. Disease status 
(de novo or relapsed/refractory) and cytogenetic abnormalities did not correlate 
with Np73 or TAp73 levels. However, AML cells with IDH1/2 mutations had 8.5-
fold lower Np73 expression than did those with wild-type IDH1/2 (1.8 ± 0.8 vs. 
15.4 ± 7.7 copies/L; p=0.0069), with a similar trend for TAp73 (49.0 ± 20.3 vs. 
138.6 ± 51.4 copies/L; p=0.056). To further explore regulation of TP73 isoforms, 
we used the MDM2 inhibitor Nutlin-3a to induce expression of p53, which is a 
transcriptional inducer of Np73. Nutlin-3a increased p73 protein levels, and 
knockdown of both TAp73 and Np73 in AML cells enhanced apoptosis induction 
(specific annexin V induction, 21.9% ± 1.3% vs. 61.3% ± 5.2%; p=0.0084 in OCI-
AML3 cells with vector control vs. Shp73, respectively), possibly due to silencing 
of Np73. AML cells with IDH1/2 mutations are more dependent on Bcl-2 than 
are those without them.1 Of note, (R)-2HG, the oncometabolite of mutant IDH1/2, 
reduced both TAp73 and Np73 levels in AML cells and increased susceptibility 
to the Bcl-2 inhibitor ABT-199. 
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Conclusion: Absolute quantitation of TP73 isoforms using ddPCR revealed 
higher expression in AML cells than in normal hematopoietic cells. Repressed 
expression of TP73 isoforms in AML cells with IDH1/2 mutations or by the 
oncometabolite (R)-2HG suggests that epigenetic modifications via (R)-2HG can 
regulate TP73 transcription and enhance the antileukemia effect by Bcl-2 
inhibition. Finally, downregulation of TP73 isoforms enhances the efficacy of 
MDM2 inhibitor against AML, suggesting a therapeutic strategy to enhance 
MDM2 inhibitor-mediated p53 activation. 
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Purpose: Chronic inflammation is known to be associated with melanoma 
progression. We sought to determine which inflammatory marker’s expression in 
stage IV melanomas is associated with outcome and whether increased 
expression of inflammatory markers in systemic non-central nervous system 
(CNS) melanoma metastasis is associated with increased risk of CNS metastasis 
and is a negative prognostic factor for overall survival. 
 
Methods: We retrospectively identified 315 patients with stage IV melanoma. 
Using a tissue microarray of systemic non-CNS metastasis specimens from 
these patients, we performed immunohistochemical analysis to measure the 
cellular expression of CD74, macrophage migration inhibitory factor, inducible 
nitric oxide synthase, nitrotyrosine, cyclooxygenase-2, and microsomal 
prostaglandin E synthase-1. We analyzed the association of these inflammatory 
33 
 
markers with median survival and time to first CNS metastasis using a Kaplan-
Meier survival curve. 
 
Results: Expression of CD74 impacted overall survival of stage IV melanoma 
(p=0.0196). The combination of CD74 positivity and macrophage migration 
inhibitory factor negativity provided an overall survival advantage in the patients 
(p=0.0264). Expression of CD74 tended to be predictive of development of or 
time to CNS metastasis, and expression of nitrotyrosine impacted development 
of or time to CNS metastasis. 
 
Conclusions: Our data validated CD74 as a useful prognostic tumor cell protein 
marker associated with favorable overall survival in stage IV melanoma patients. 
Nitrotyrosine expression was associated with increased time to CNS metastasis. 
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dilated cardiomyopathy in laminopathy 
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Lamin A/C (LMNA) is a major component of the inner nuclear membrane and is 
involved in regulation of gene expression. Mutations of the LMNA gene cause a 
heterogeneous group of diseases that are collectively referred to as 
laminopathies. Cardiac involvement is one of the most prominent features of 
laminopathies, presenting with dilated cardiomyopathy (DCM), conduction 
defects, and sudden death. Molecular mechanisms involved in the pathogenesis 
of cardiac phenotypes in laminopathies are not well known. To gain insight into 
molecular pathogenesis of DCM caused by LMNA deficiency, the Lmna gene 
was deleted exclusively in cardiac myocytes (Myh6-Cre:LmnaFlox). Homozygous 
(Myh6-Cre:LmnaF/F) mice were born at the expected Mendelian ratio and had 
normal cardiac function and histology at 2 weeks of age. However, the mice had 
progressive cardiac dilatation and dysfunction, interstitial fibrosis, and increased 
apoptosis and died by 4 weeks of age. Heterozygous mice (Myh6-Cre:LmnaW/F) 
have a milder phenotype that starts at 6 months of age. To identify transcriptomic 
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changes that precede cardiac dilatation and dysfunction, cardiac myocytes were 
isolated from 2-week-old wild-type and Myh6-Cre:LmnaF/F mice and analyzed 
using RNA sequencing. A total of 1420 genes were differentially expressed in 
wild-type and Myh6-Cre:LmnaF/F myocytes. Pathway analysis of differentially 
expressed genes demonstrated enrichment of inflammatory, epithelial-to-
mesenchymal transition, and cell death pathways, whereas mitochondrial 
oxidative function, adipogenesis, and fatty acid metabolism pathways were 
depressed in Myh6-Cre:LmnaF/F mice. Ingenuity Pathway Analysis identified BET 
bromodomain protein 4 (BRD4) among the top five upstream regulators of the 
differentially expressed genes. Consistently, treatment with the BET 
bromodomain inhibitor JQ1 improved survival and cardiac function in the Myh6-
Cre:LmnaF/F mice over that in untreated and vehicle-treated Myh6-Cre:LmnaF/F 
mice. Effects on the myocardial phenotypes (e.g., apoptosis, fibrosis) are being 
analyzed. 
 
In conclusion, LMNA deficiency results in dysregulation of a large number genes, 
including BRD4 target genes that precede the onset of cardiac dysfunction and 
fibrosis. The findings point to the prominent role of BRD4 in development of 
cardiac dysfunction in cases of myocyte-specific LMNA deficiency and identify 
this protein as a therapeutic target DCM caused by LMNA deficiency. 
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Emerging role for membrane therapy in shaping aberrant Wnt 
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Wnt signaling is the major driving force behind homeostatic self-renewal of the 
intestinal crypt. Dysregulation of Wnt signaling has been linked with cancer in 
multiple types of tissue. For example, about 90% of colorectal cancer (CRC) 
cases are associated with defects in this pathway. In the vast majority (>80%) of 
sporadic CRC cases, sequencing evidence indicates the presence of mutations 
of adenomatous polyposis coli (APC). This gatekeeping gene is a key regulator 
of Wnt signaling. Loss of Apc function causes aberrant stabilization of -catenin, 
a crucial step in CRC initiation. Notably, attempts to target this pathway using 
drugs still face multiple hurdles due to poor tumor-cell targeting and kill 
specificity, negative side effects associated with required long-term treatment, 
and poorly understood mechanisms of action. Consequently, additional 
mechanistic insight into the Wnt signaling pathway is urgently needed to develop 
toxicologically innocuous therapeutic approaches. With respect to Wnt signaling 
transduction, two key plasma membrane receptors, LRP5/6 and Frizzled (Fz), 
require lipid raft localization and nanoclustering with cytosolic Dvl and Axin for 
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efficient signaling. Various effectors (e.g., nystatin, Dkk1) that disrupt lipid raft 
dynamics alter LRP5/6 and Fz clustering and downstream signaling, leading to a 
reduction in -catenin stabilization. Thus, we examined the effect of oncogenic 
APC (oAPC) on key colonocyte plasma membrane lipid-lipid, lipid-protein, and 
protein-protein interactions of Wnt-associated effectors in a conditionally mutated 
mouse model of CRC and oAPC-expressing cell lines. We showed for the first 
time that oAPC significantly increased the levels of free cholesterol in the plasma 
membrane, a major component of lipid rafts known to selectively activate 
canonical Wnt signaling. Moreover, oAPC significantly increased lipid-lipid 
interactions, for example, plasma membrane rigidity and lipid raft stability. We 
subsequently examined the effect of oAPC on the spatiotemporal dynamics 
(protein-protein clustering) of Wnt signaling receptors/effectors in a CRC cell line 
model expressing oAPC. oAPC significantly increased LRP5/6 and Fz 
homoclustering and LRP5/6-Fz heteroclustering, resulting in enhancement of 
Wnt signaling. Of note, the dysregulation of plasma membrane physical/chemical 
properties described above was exacerbated when a constitutively active form of 
-catenin was expressed in oAPC cell lines. Collectively, these findings 
demonstrate that oAPC can directly perturb cholesterol homeostasis in 
colonocytes, thereby altering lipid raft stability, plasma membrane LRP5/6 and Fz 
clustering, and downstream Wnt signaling. Thus, loss of plasma membrane 
homeostasis is a key step in CRC initiation, demonstrating the importance of 
developing membrane-targeted therapies. 
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Ras signaling originates from transient nanoscale compartmentalized regions of 
the plasma membrane composed of specific proteins and lipids. The highly 
specific lipid composition of these nanodomains, termed nanoclusters, facilitates 
effector recruitment and therefore influences signal transduction. This suggests 
that Ras nanocluster proteolipid composition represents a novel target for future 
chemoprevention interventions. Evidence demonstrates that consumption of fish 
oil containing long-chain n-3 polyunsaturated fatty acids such as 
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eicosapentaenoic acid (20:55,8,11,14,17) and docosahexaenoic acid 
(22:64,7,10,13,16,19) may reduce colon cancer risk in humans, yet the mechanism 
underlying this effect is unknown. As described herein, we demonstrated that 
dietary n-3 polyunsaturated fatty acids reduce the lateral segregation of 
cholesterol-dependent and -independent nanoclusters, suppressing phosphatidic 
acid-dependent oncogenic KRas effector interactions, via their physical 
incorporation into plasma membrane phospholipids. This results in attenuation of 
oncogenic Ras-driven colonic hyperproliferation in both Drosophila and murine 
models. These findings demonstrate the unique properties of dietary n-3 
polyunsaturated fatty acids in the shaping of Ras nanoscale proteolipid 
complexes and support the emerging role of plasma membrane-targeted 
therapies. 
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Background: The role of the protocadherin gene FAT1 in glioma tumorigenesis 
is contradictory. FAT1 modulates stemness genes, including REST, SOX2, 
OCT4, and NESTIN, in the glioblastoma cell lines U87MG and A172 under 
hypoxic conditions. Whereas hypoxia increases the expression of these 
stemness markers in U87MG and A172 cells, FAT1 knockdown results in their 
downregulation under the same conditions. Hence, we investigated the 
relationship of FAT1 with REST in a new cell model, patient-derived glioblastoma 
stem cells (GSCs), which is close to in vivo tumors. 
 
Methods: High-REST GSC lines (HR-GSC1 and HR-GSC2) had been derived 
and established from glioblastoma patients in our laboratory. They were 
maintained under in vitro stemness conditions using Dulbecco’s modified Eagle’s 
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medium-F12 medium and epidermal growth factor and B27 supplements. 
Transient small interfering RNA-mediated FAT1 knockdown was performed in 
GSCs exposed to normoxia (20% O2) and severe hypoxia (0.2% O2). 
Quantitative polymerase chain reaction was performed to analyze the expression 
of FAT1, REST, and other stemness marker genes in FAT1 small interfering 
RNA-exposed cells relative to that in control small interfering RNA-exposed cells 
under both normoxia and hypoxia. 
 
Results: REST mRNA expression increased upon exposure to hypoxia in both 
HR-GSC1 and HR-GSC2. On one hand, in HR-GSC1, FAT1 knockdown led to 
decreased REST mRNA levels under normoxia as well as hypoxia. This was 
accompanied by decreases in SOX2 and OCT4 mRNA levels. On the other 
hand, in HR-GSC2, REST mRNA levels increased after FAT1 knockdown under 
both normoxia and hypoxia. SOX2 and OCT4 levels in HR-GSC2 also increased 
after FAT1 knockdown under normoxia and hypoxia. 
 
Conclusions: We observed differential modulation of REST and other stemness 
genes by FAT1 in GSCs as compared with that in the glioblastoma cell lines 
U87MG and A172. Whereas HR-GSC1 is a cell model similar to U87MG and 
A172, HR-GSC2 exhibits divergent behavior upon FAT1 knockdown. Our results 
support the context-dependent behavior of FAT1 in glioma and imply that FAT1-
mediated stemness modulation depends on intervening molecular mechanisms 
operating in the different cell types. Such patient-to-patient genetic variation 
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reflects implications in determining personalized therapeutic approaches and 
should be considered for further study. 
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T-cell checkpoint blockade with anti-cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4) and anti-programmed cell death protein 1(PD-1) therapy is effective 
against “hot” tumors like melanoma with pre-existing immune infiltrates. 
However, “cold” tumors like prostate and pancreatic cancers respond poorly. We 
found that hypoxic zones are prevalent across preclinical prostate cancers and 
resist T-cell infiltration even in the context of CTLA-4 and PD-1 blockade. 
Hypoxia fosters metabolic alterations, resulting in extracellular acidification of the 
microenvironment, depletion of essential amino acids like arginine and 
tryptophan, accumulation of extracellular adenosine, dense expression of 
inhibitory ligands like PD-L1 and recruitment and polarization of immature 
myeloid cells into immunosuppressive myeloid-derived suppressor cells and 
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tumor-associated macrophages, all of which dampen T-cell responses. For 
prostate cancer, increased hypoxia has been strongly correlated with more 
aggressive disease. We used the hypoxia-activated prodrug TH-302 to disrupt 
tumor hypoxia and showed that it cooperated with checkpoint blockade in curing 
80% of mice of TRAMP-C2 prostate tumors. This combination therapy increased 
T-cell infiltration into previously hypoxic areas concomitant with reduced 
immunosuppressive myeloid cell infiltration and suppressive function. Tumors 
from mice receiving TH-302 and checkpoint blockade exhibited persistent defects 
in their ability to replenish the myeloid stroma. In addition, tumor-infiltrating T 
cells from TH-302– and checkpoint blockade-treated mice had greater effector 
cytokine production and mitochondrial biomass than did their untreated 
counterparts. Spontaneous prostate tumors in TRAMP transgenic mice, which 
are completely resistant to checkpoint blockade, exhibited minimal 
adenocarcinoma burden at 36 weeks of age and no evidence of neuroendocrine 
tumors in response to the combination therapy. Survival of Pb-Cre4 and 
Ptenpc−/−Smad4pc−/− mice with highly aggressive prostate adenocarcinoma was 
also significantly extended by the combination of TH-302 and checkpoint 
blockade. This combination of hypoxia disruption and T-cell checkpoint blockade 
may render some of the most therapeutically resistant cancers sensitive to 
immunotherapy. 
 
 
 
45 
 
HDAC6 inhibition prevents cisplatin-induced peripheral 
neuropathy in a T cell-dependent manner 
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Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a serious 
health concern for cancer patients receiving chemotherapy, affecting more than 
60% of this population. Currently, U.S. Food and Drug Administration-approved 
drugs to effectively manage CIPN are lacking, emphasizing the urgent need to 
identify novel agents to prevent CIPN. Histone deacetylase 6 (HDAC6) is a 
cytosolic deacetylase whose substrates include a-tubulin and Hsp90. We have 
shown that inhibition of HDAC6 reverses established CIPN in a mouse model 
through resolution of chemotherapy-induced mitochondrial dysfunction and 
axonal transport deficits. Currently, the HDAC6 inhibitor ACY-1215 is used in 
clinical trials as add-on therapy for cancer. Therefore, we sought to determine if 
adding this HDAC6 inhibitor to chemotherapy prevents CIPN. 
 
Goals: To investigate whether administration of the HDAC6 inhibitor ACY-1215 
during cisplatin-based treatment prevents CIPN and, if so, to understand its 
underlying mechanism. 
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Methods: CIPN was induced by two cycles of five daily intraperitoneal cisplatin 
injections. ACY-1215 was given via oral gavage 1 hour prior to each cisplatin 
injection. Mechanical allodynia in wild-type, T-cell-deficient Rag2-knockout 
(Rag2-/-) and HDAC6-knockout (HDAC6-/-) mice was measured using the von 
Frey test. Mitochondrial bioenergetics were measured using an XF24 Flux 
Analyzer. For adoptive T-cell transfer, T cells were isolated from the spleens of 
wild-type and HDAC6-/- mice and injected intravenously into Rag2-/- mice 1 week 
prior to treatment. 
 
Results: Our data demonstrated that coadministration of ACY-1215 prevents 
cisplatin-induced mechanical allodynia and neuronal mitochondrial dysfunction. 
HDAC6-/- mice did not experience cisplatin-induced mechanical allodynia or 
mitochondrial dysfunction, indicating target specificity of the inhibitor. Intriguingly, 
we found that the protective effects of the HDAC6 inhibitor did not occur in Rag2-
/- mice without mature T and B lymphocytes. Reconstitution of Rag2-/- mice with 
CD3+ T cells restored the effect of the inhibitor, suggesting that HDAC6 inhibition 
prevents CIPN in a T-cell-dependent manner. To determine whether HDAC6 
inhibition in T cells is sufficient to protect against CIPN, we reconstituted Rag2-/- 
mice with HDAC6-/- T cells. However, ablation of HDAC6 in T cells alone was not 
sufficient to prevent CIPN. 
 
Conclusions: Our results demonstrated that inhibition of HDAC6 during 
chemotherapy prevents CIPN in a T-cell-dependent manner. Our findings 
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strengthen the rationale for using HDAC6 inhibitors like ACY-1215 to not only 
improve cancer therapy but also prevent CIPN. 
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vascular remodeling 
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Background: High-dose chemotherapy is the standard of care for most solid 
tumors, including Ewing sarcoma (ES), an aggressive bone and soft tissue 
sarcoma. High doses of chemotherapy are needed in part because of inefficient 
drug delivery to the tumor due to a hyperpermeable tumor vasculature. Improving 
tumor vessel function may deliver more chemotherapy and thus increase drug 
efficacy. One means of inducing tumor vascular normalization may be increasing 
shear stress. Shear stress is the physiological force created by blood flow 
important for maintaining vessel functionality. We found that increasing shear 
stress via moderate exercise caused tumor vascular normalization, increasing 
functionality and chemotherapy delivery in ES-bearing mice. However, the 
molecular mechanisms regulating tumor vasculature response to exercise are 
unclear. Vessel permeability is partly controlled by the G-protein-coupled 
receptor sphinosine-1-phsosphate receptor 1 (S1PR1) in endothelial cells (ECs). 
S1PR1 expression is induced by shear stress in a ligand-independent manner. 
We hypothesize that moderate exercise corrects tumor vessel hyperpermeability 
and thus improves chemotherapy delivery by increasing S1PR1 signaling. We 
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further hypothesize that S1PR1 on ES endothelium is necessary for enhanced 
tumor vascular function and chemotherapy delivery. In this study, we used 
treatment with a pharmacological inhibitor (FTY720) and activator (SEW2871) of 
S1PR1 receptor or exercise to determine whether modulation of this pathway is a 
clinically relevant means of enhancing chemotherapeutic efficacy in ES mouse 
models. 
 
Experimental Design: TC71 and A673 ES cells from tumor-bearing mice were 
treated with 1) doxorubicin and/or exercise, 2) doxorubicin and/or FTY720 
(antagonist of S1PR1), or 3) doxorubicin and/or SEW2871 (agonist of S1PR1). 
Tumor growth, vascular architecture, and permeability to high-molecular weight 
dextran were characterized. FTY720 antagonism and SEW2871 agonism of 
S1PR1 were confirmed using Western blot analysis of downstream mediators of 
S1PR1 signaling (S1PR1, pERK1/2, and pAKT) in lung and tumor ECs. 
 
Results: Moderate aerobic exercise markedly reduced vascular leakiness and 
improved chemotherapy efficacy in TC71 tumor-bearing mice. 
Immunohistochemical analysis demonstrated that exercise increased the 
expression of S1PR1 in tumor ECs. In A673 and TC71 ES-bearing animals, 
FTY720 administration inhibited S1PR1 expression in tumor and lung ECs. Also, 
the ratio of downstream S1PR1 mediators pERK1/2/ERK1/2 and pAkt1/Akt1 was 
reduced in lung homogenates, demonstrating S1PR1 signaling inhibition by 
FTY720. The vasculature of tumors in mice given FTY720 was characterized by 
50 
 
increased vascular permeability. In vivo, S1PR1 inhibition combined with 
doxorubicin increased vascular leakiness and reduced doxorubicin efficacy when 
compared with chemotherapy alone. In contrast, S1PR1 activation by SEW2871 
administration substantially increased the ratio of pERK1/2/ERK1/2 in tumor ECs 
demonstrating S1PR1 signaling activation, reduced tumor vascular permeability, 
and increased doxorubicin efficacy. 
 
Conclusions: Moderate aerobic exercise is a nontoxic and cost-effective 
adjuvant for remodeling tumor vasculature and improving the efficacy of 
anticancer therapies. Exercise is also a nonpharmacological activator of S1PR1 
signaling on tumor endothelium. Increased expression or activation of S1PR1 on 
tumor endothelium may be necessary to reduce the vascular hyperpermeability 
of blood vessels and improve chemotherapy delivery. Further work using genetic 
deletion of S1PR1 in combination with exercise is needed to determine whether 
exercise-induced vascular remodeling is S1PR1-dependent. 
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Lung cancer remains the most lethal human cancer, with significantly high 
morbidity and mortality rates due to metastasis. Current understanding of cancer 
metastasis is limited due to its largely unidentified specific molecular drivers, the 
complexity of the metastatic process, and its underlying mechanisms, which 
remain poorly understood. Non-small cell lung cancer patients have dismal 
survival, so effective therapeutic interventions to improve patient outcome are 
urgently needed. We recently employed a comprehensive in vivo gain-of-function 
screen to identify genes that are potential critical drivers of metastasis. Using this 
approach, we identified MAP3K12-binding inhibitory protein (MBIP), a gene 
capable of inducing the metastatic cascade in Kras/p53-mutant mice. MBIP is 
part of the Ada2a-containing complex and is essential for histone modification. In 
addition, it inhibits MAP3K12, thereby activating the JNK/SAPK pathway. We 
found that elevated MBIP expression in 393P nonmetastatic epithelial cells 
enhanced their ability to invade, migrate, and form invasive protrusions in three-
dimensional cultures. Conversely, MBIP depletion in 344SQ mesenchymal cells 
not only inhibited their migratory and invasive capacity but also reduced their 
aggressiveness in a three-dimensional collagen Matrigel matrix. The Cancer 
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Genome Atlas and Oncomine data set and immunohistochemical analyses 
revealed a sharp increase in mRNA and protein expression corresponding with 
markedly elevated expression of MBIP. Although MBIP may play a pivotal role in 
cell motility and invasion in vitro, little is known about its biology in lung cancer 
metastasis. To that end, we induced MBIP overexpression or knockdown in 
Kras/p53-expressing cells in mice and examined tumorigenesis and lung 
metastasis in the mice relative to those in controls. We found that MBIP-
overexpressing (393P) mice exhibited markedly greater lung tumor burdens and 
growth and numbers of metastatic nodules than did control mice. Moreover, 
when we injected MBIP-knockdown cells (344SQ) into mice, we noted 
considerably fewer metastatic nodules than in the controls. To gain global insight 
into the impact of MBIP on signaling pathways in metastatic non-small cell lung 
cancer, we employed Ingenuity Pathway Analysis coupled with microRNA 
database searches (TargetScan, miRWalk, and PicTar) to survey MBIP. 
Ingenuity Pathway Analysis identified signaling nodules involved in the MAPK 
pathway, whereas it identified the microRNA miR-183, which is known to regulate 
Ezrin (a cytoskeletal protein important for invadopodia formation), as an MBIP 
target. We confirmed the pathway analysis results using Western blotting and 
immunohistochemistry, demonstrating increased levels of phosphorylated p38, 
Erk1/2, and Jnk in cells with elevation of MBIP expression. Also, Ezrin mRNA 
and phosphorylated protein levels were higher in metastatic nodules than in 
corresponding tumors in control mice. In addition, we observed epithelial-to-
mesenchymal transition as tumors metastasized to the lungs. Taken together, 
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our data demonstrated that the metastatic function of MBIP is to promote cell 
motility and invasion of non-small cell lung cancer by inducing epithelial-to-
mesenchymal transition and activating MAPK oncogenic signaling. 
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PD-L1 checkpoint blockade in combination with MEK inhibition 
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1Department of Thoracic/Head and Neck Medical Oncology, The University of 
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Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related 
deaths due to late-stage disease presentation, metastasis, and resistance to 
conventional treatment, suggesting a need for targeted therapies. About 30% of 
patients with lung adenocarcinoma possess an activating KRAS mutation, and 
pharmacological drugs that can specifically and effectively target this oncogenic 
protein are lacking. Although mitogen-activated protein kinase kinase (MEK) is a 
canonical downstream effector of activated mutant KRAS in the mitogen-
activated protein kinase (MAPK) signaling pathway, MEK inhibitors have failed to 
yield clinical benefit for KRAS-mutant cancers. To investigate this, we evaluated 
in vivo hairpin screens, proteomic profiles, and large patient data sets and 
observed an inverse correlation between MEK inhibitor sensitivity and a Zeb1-
dependent epithelial-to-mesenchymal transition (EMT) state in tumors. 
Additionally, previous work by our group demonstrated that EMT contributes to 
an immunosuppressive tumor microenvironment through increased PD-L1 
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expression. Herein we show that treatment of lung cancer cells with an MEK 
inhibitor upregulates Zeb1 and PD-L1 whereas conversely, PD-L1 immune 
checkpoint blockade downregulates Zeb1 and enhances MAPK signaling. 
Combination of the MEK inhibitor with PD-L1 blockade had a synergistic effect in 
reducing drug-resistant lung tumor growth and metastasis, including MEK 
inhibitor-induced metastasis. The decrease in tumor growth and metastasis 
resulting from the dual treatment correlated with a synergistic increase in total 
and memory/effector CD8+ T-cell infiltration followed by a synergistic decrease in 
naïve and exhausted CD8+ T-cell populations. In future studies, researchers will 
aim to perform coclinical trials of the combination therapy using autochthonous 
murine models and further delineate the mechanism behind T-cell recruitment 
and activation by the combinatorial treatment. 
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The role of activated Beta-catenin/Wnt signaling in the 
progression of castration resistance of prostate cancer in bone 
Justin M. Roberts, Estefania Labanca, Peter Shepherd, Jun Yang, Michael W. 
Starbuck, Nora M. Navone 
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Bone metastases typically develop in patients with advanced prostate cancer 
(PCa). These metastases are osteoblastic (bone-forming) and constitute the 
main cause of morbidity and mortality. Androgen deprivation is commonly used 
to treat bone metastases of PCa, but responses to such therapy are short, and 
the disease eventually progresses to a castration-resistant form. Bone is the 
primary site of castration-resistant PCa (CRPC) progression. Further 
development of therapies for bone metastases of PCa requires an understanding 
of the mechanisms underlying the growth of CRPC in bone. Clinical and 
laboratory-based investigations have implicated a role for PCa cell-bone cell 
interaction in the growth of PCa and have demonstrated that osteoblasts produce 
factors that favor the growth and survival of PCa cells. Collectively, these 
observations strongly suggest that PCa cells interact with osteoblasts and that 
this interaction contributes to the growth of PCa in bone. In a recent study, 18% 
of patients with metastatic CRPC harbored alterations in the Wnt canonical 
pathway, including hotspot mutations of -catenin (-cat), the molecular node of 
the Wnt canonical pathway that leads to pathway activation. This report is in 
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agreement with previous published reports of nuclear -cat accumulation, an 
indirect measure of Wnt canonical pathway activation, in 20-40% of advanced 
PCas. We previously reported that an MDA-PCa-118b patient-derived xenograft 
developed in our laboratory harbors a -cat mutation (D32G) and has an 
activated Wnt canonical pathway. MDA-PCa-118b induces an osteoblastic 
reaction when it is implanted in the bone of mice in vivo. In vitro, MDA-PCa-118b 
induces osteoblast proliferation in coculture. In contrast, the PCa cell line PC3 
induces osteolytic lesions in vivo and in vitro and inhibits osteoblast proliferation 
in coculture. Strikingly, expression of -cat mutated at D32G in PC3 cells 
reverses the osteoblast-inhibitory effect of PC3 cells, resulting in increased 
proliferation of osteoblasts when grown in coculture. We therefore hypothesize 
that -cat/Wnt signaling in PCa cells mediates the PCa-bone interaction that 
favors PCa growth in bone. Our future studies will focus on the importance of -
cat mutations recently identified in patients with metastatic CRPC and 
determining whether these mutations also result in an osteoblastic phenotype, 
which in turn supports growth of PCa in bone. Additionally, we are screening our 
collection of PCa patient-derived xenograft lines for increased -cat expression 
using immunohistochemistry and will sequence DNA from patient-derived 
xenograft lines that demonstrate increased nuclear -cat expression to test them 
for activating mutations of -cat. Our aim is to gain insight into the mechanism of 
the paracrine interaction between PCa cells and bone that supports the growth of 
PCa bone lesions, with the ultimate goal of developing therapies to block these 
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interactions and reduce the morbidity and mortality associated with metastatic 
disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
Comprehensive molecular characterization of the Hippo 
signaling pathway in cancer 
Yumeng Wang1,2, Xiaoyan Xu2,3, Dejan Maglic4-6, Michael T. Dill4-6, Kamalika 
Mojumdar2, Kwok-Shing Ng7, Kang Jin Jeong7, Yiu-Huen Tsang8, Chad J. 
Creighton8,9, Gordon B. Mills7, Fernando Camargo4-6, Han Liang2,7 
1Graduate Program in Quantitative and Computational Biosciences, Baylor 
College of Medicine, Houston, TX; 2Department of Bioinformatics and 
Computational Biology, The University of Texas MD Anderson Cancer Center, 
Houston, TX; 3Department of Pathophysiology, College of Basic Medicine 
Science, China Medical University, Shenyang, Liaoning Province, China; 4Stem 
Cell Program, Boston Children's Hospital, Boston, MA; 5Department of Stem Cell 
and Regenerative Biology, Harvard University, Cambridge, MA; 6Harvard Stem 
Cell Institute, Boston, MA; 7Department of Systems Biology, The University of 
Texas MD Anderson Cancer Center, Houston, TX; 8Department of Human 
Genetics, Baylor College of Medicine, Houston, TX; 9Duncan Cancer Center-
Biostatistics, Baylor College of Medicine, Houston, TX. 
 
Hippo signaling moderates cell proliferation and differentiation and is recognized 
as a key tumor suppressor pathway in cancer. We performed comprehensive 
molecular characterization of 19 Hippo core genes in 9125 tumor samples across 
33 cancer types using multidimensional “omic” data from The Cancer Genome 
Atlas. We systematically identified somatic drivers among Hippo genes and the 
related microRNA regulators, including experimentally characterized YAP and 
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TAZ mutation effects and miR-590 and miR-200a regulation for TAZ. Hippo 
pathway activity is best characterized by a YAP/TAZ transcriptional target 
signature of 22 genes with robust prognostic power across cancer types that is 
correlated with epithelial-to-mesenchymal transition, DNA damage, and 
infiltrating immune cell composition. Our elastic-net integrated modeling further 
revealed cancer type-specific pathway regulators and associated cancer drivers. 
Our results also highlighted the importance of Hippo signaling in squamous cell 
cancers, characterized by frequent amplification of YAP/TAZ, high expression 
heterogeneity, and significant prognostic patterns. This study provides a 
systematic view of Hippo molecular aberrations in different tumor contexts and 
lays the foundation for developing Hippo-targeted therapeutic strategies. 
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vesiculation through decreasing membrane stiffness 
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Extracellular vesicles (EVs), including exosomes and microvesicles, play critical 
roles in intercellular communication by exchanging proteins, lipids, and genetic 
materials between cells. However, the origin and biogenesis of these vesicles 
remain unclear. Authors have noted that almost all EVs present the anionic 
membrane lipid phosphatidylserine (PS) on their outer leaflets, which is in 
opposition to their cells of origin, which almost exclusively retain PS in the 
cytoplasmic leaflet. The “scrambling” of PS from the inner to the outer leaflet of 
the bilayer is facilitated by the lipid channel Ano6. This process of lipid 
scrambling is implicated in a variety of physiological contexts, including apoptotic 
cell removal, bone mineralization, viral infection, myoblast fusion, erythrocyte 
clearance, synaptic pruning, and blood coagulation. However, the biophysical 
role of PS externalization in the formation of extracellular vesicles remains a 
mystery. Using micrometer-sized giant plasma membrane vesicles produced by 
membrane blebbing from mouse B cells (BaF3), we studied the role of PS 
externalization in membrane vesiculation. We first found that a scramblase (i.e., 
Ano6)-knockout BaF3 cell line was deficient in producing large vesicles when 
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compared with the wild-type cell line, whereas Ano6-retransformed knockouts 
rescued the phenotype, indicating that PS externalization is necessary for 
membrane budding. Importantly, using fluorescence lifetime imaging microscopy 
with a reporter of lipid packing (Di4), we found that PS exposure led to a 
decrease in plasma membrane packing, potentially making the membrane softer 
for bending and thus facilitating membrane budding. To confirm this, we 
artificially decreased the lipid order on the plasma membrane by increasing the 
incubation temperature or treating cells with methyl--cyclodextrin. Under all 
conditions that reduced membrane stiffness, the PS externalization-deficient 
Ano6-knockout cell line efficiently produced large vesicles, confirming the crucial 
role of membrane stiffness in cell vesiculation. In summary, our study uncovered 
that membrane softening due to lipid scrambling was the major biophysical 
mechanism by which PS externalization regulated membrane vesiculation. 
Notably, membrane budding was controlled only by PS exposure, not by the 
overall PS level.  
